Keros Therapeutics
KROS · NASDAQ
$11.40+$0.34 (+3.07%)TodayMarket closed ·
Prev close $11.06
EPS: actual vs estimate
Beat the estimate in 3 of the last 8 quarters, by 559.2% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$1.37 | -$1.45 | −6.1% |
| Q1 FY26 | -$1.04 | -$1.21 | −16.0% |
| Q4 FY25 | -$0.6413 | -$0.86 | −34.1% |
| Q3 FY25 | -$1.07 | -$0.18 | +83.1% |
| Q2 FY25 | -$1.15 | -$0.76 | +34.2% |
| Q1 FY25 | -$0.2479 | $3.62 | +1560.3% |
| Q4 FY24 | -$1.00 | -$1.14 | −13.7% |
| Q3 FY24 | -$1.30 | -$1.41 | −8.1% |
Earnings calls
- Goldman Sachs 47th Annual Global Healthcare Conference 2026
- Morgan Stanley 19th Annual Global Healthcare Conference
- Jefferies 2021 Virtual Healthcare Conference
- H.C. Wainwright Virtual Global Life Sciences Conference
- SVB Leerink 10th Annual Global Healthcare Conference 2021
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.